Anissa A Widjaja1, Shamini G Shekeran2, Eleonora Adami2,3, Joyce G Wei Ting2, Jessie Tan4, Sivakumar Viswanathan2, Sze Yun Lim2, Puay Hoon Tan2,5,6, Norbert Hübner3,7,8, Thomas Coffman2, Stuart A Cook1,4,9. 1. Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, Singapore anissa.widjaja@duke-nus.edu.sg stuart.cook@duke-nus.edu.sg. 2. Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, Singapore. 3. Cardiovascular and Metabolic Sciences, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany. 4. National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore. 5. Department of Anatomical Pathology, Singapore General Hospital, Singapore, Singapore. 6. Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. 7. DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany. 8. Charité-Universitätsmedizin, Berlin, Germany. 9. MRC-London Institute of Medical Sciences, Hammersmith Hospital Campus, London, UK.
Abstract
BACKGROUND: Alport syndrome is a genetic disorder characterized by a defective glomerular basement membrane, tubulointerstitial fibrosis, inflammation, and progressive renal failure. IL-11 was recently implicated in fibrotic kidney disease, but its role in Alport syndrome is unknown. METHODS: We determined IL-11 expression by molecular analyses and in an Alport syndrome mouse model. We assessed the effects of a neutralizing IL-11 antibody (×203) versus an IgG control in Col4a3-/- mice (lacking the gene encoding a type IV collagen component) on renal tubule damage, function, fibrosis, and inflammation. Effects of ×203, the IgG control, an angiotensin-converting enzyme (ACE) inhibitor (ramipril), or ramipril+X203 on lifespan were also studied. RESULTS: In Col4a3-/- mice, as kidney failure advanced, renal IL-11 levels increased, and IL-11 expression localized to tubular epithelial cells. The IL-11 receptor (IL-11RA1) is expressed in tubular epithelial cells and podocytes and is upregulated in tubular epithelial cells of Col4a3-/- mice. Administration of ×203 reduced albuminuria, improved renal function, and preserved podocyte numbers and levels of key podocyte proteins that are reduced in Col4a3-/- mice; these effects were accompanied by reduced fibrosis and inflammation, attenuation of epithelial-to-mesenchymal transition, and increased expression of regenerative markers. X203 attenuated pathogenic ERK and STAT3 pathways, which were activated in Col4a3-/- mice. The median lifespan of Col4a3-/- mice was prolonged 22% by ramipril, 44% with ×203, and 99% with ramipril+X203. CONCLUSIONS: In an Alport syndrome mouse model, renal IL-11 is upregulated, and neutralization of IL-11 reduces epithelial-to-mesenchymal transition, fibrosis, and inflammation while improving renal function. Anti-IL-11 combined with ACE inhibition synergistically extends lifespan. This suggests that a therapeutic approach targeting IL-11 holds promise for progressive kidney disease in Alport syndrome.
BACKGROUND: Alport syndrome is a genetic disorder characterized by a defective glomerular basement membrane, tubulointerstitial fibrosis, inflammation, and progressive renal failure. IL-11 was recently implicated in fibrotic kidney disease, but its role in Alport syndrome is unknown. METHODS: We determined IL-11 expression by molecular analyses and in an Alport syndrome mouse model. We assessed the effects of a neutralizing IL-11 antibody (×203) versus an IgG control in Col4a3-/- mice (lacking the gene encoding a type IV collagen component) on renal tubule damage, function, fibrosis, and inflammation. Effects of ×203, the IgG control, an angiotensin-converting enzyme (ACE) inhibitor (ramipril), or ramipril+X203 on lifespan were also studied. RESULTS: In Col4a3-/- mice, as kidney failure advanced, renal IL-11 levels increased, and IL-11 expression localized to tubular epithelial cells. The IL-11 receptor (IL-11RA1) is expressed in tubular epithelial cells and podocytes and is upregulated in tubular epithelial cells of Col4a3-/- mice. Administration of ×203 reduced albuminuria, improved renal function, and preserved podocyte numbers and levels of key podocyte proteins that are reduced in Col4a3-/- mice; these effects were accompanied by reduced fibrosis and inflammation, attenuation of epithelial-to-mesenchymal transition, and increased expression of regenerative markers. X203 attenuated pathogenic ERK and STAT3 pathways, which were activated in Col4a3-/- mice. The median lifespan of Col4a3-/- mice was prolonged 22% by ramipril, 44% with ×203, and 99% with ramipril+X203. CONCLUSIONS: In an Alport syndrome mouse model, renal IL-11 is upregulated, and neutralization of IL-11 reduces epithelial-to-mesenchymal transition, fibrosis, and inflammation while improving renal function. Anti-IL-11 combined with ACE inhibition synergistically extends lifespan. This suggests that a therapeutic approach targeting IL-11 holds promise for progressive kidney disease in Alport syndrome.
Authors: Jennifer C Hood; John Dowling; John F Bertram; Richard J Young; Clive Huxtable; Wayne Robinson; Judy Savige Journal: Nephrol Dial Transplant Date: 2002-11 Impact factor: 5.992
Authors: Anissa A Widjaja; Brijesh K Singh; Eleonora Adami; Sivakumar Viswanathan; Jinrui Dong; Giuseppe A D'Agostino; Benjamin Ng; Wei Wen Lim; Jessie Tan; Bhairav S Paleja; Madhulika Tripathi; Sze Yun Lim; Shamini Guna Shekeran; Sonia P Chothani; Anne Rabes; Martina Sombetzki; Eveline Bruinstroop; Lio Pei Min; Rohit A Sinha; Salvatore Albani; Paul M Yen; Sebastian Schafer; Stuart A Cook Journal: Gastroenterology Date: 2019-05-09 Impact factor: 22.682
Authors: Oliver Gross; Burkhard Tönshoff; Lutz T Weber; Lars Pape; Kay Latta; Henry Fehrenbach; Baerbel Lange-Sperandio; Hildegard Zappel; Peter Hoyer; Hagen Staude; Sabine König; Ulrike John; Jutta Gellermann; Bernd Hoppe; Matthias Galiano; Britta Hoecker; Rasmus Ehren; Christian Lerch; Clifford E Kashtan; Markus Harden; Jan Boeckhaus; Tim Friede Journal: Kidney Int Date: 2020-01-17 Impact factor: 10.612
Authors: M M Shull; I Ormsby; A B Kier; S Pawlowski; R J Diebold; M Yin; R Allen; C Sidman; G Proetzel; D Calvin Journal: Nature Date: 1992-10-22 Impact factor: 49.962
Authors: Yuhei Kirita; Haojia Wu; Kohei Uchimura; Parker C Wilson; Benjamin D Humphreys Journal: Proc Natl Acad Sci U S A Date: 2020-06-22 Impact factor: 11.205
Authors: Wei-Wen Lim; Ben Corden; Benjamin Ng; Konstantinos Vanezis; Giuseppe D'Agostino; Anissa A Widjaja; Wei-Hua Song; Chen Xie; Liping Su; Xiu-Yi Kwek; Nicole G Z Tee; Jinrui Dong; Nicole S J Ko; Mao Wang; Chee Jian Pua; Muhammad H Jamal; Beeyong Soh; Sivakumar Viswanathan; Sebastian Schafer; Stuart A Cook Journal: Sci Rep Date: 2020-10-20 Impact factor: 4.379
Authors: Eleonora Adami; Sivakumar Viswanathan; Anissa A Widjaja; Benjamin Ng; Sonia Chothani; Nevin Zhihao; Jessie Tan; Pei Min Lio; Benjamin L George; Umut Altunoglu; Kakaly Ghosh; Bhairav S Paleja; Sebastian Schafer; Bruno Reversade; Salvatore Albani; Andrea Low Hsiu Ling; Steven O'Reilly; Stuart A Cook Journal: Rheumatology (Oxford) Date: 2021-12-01 Impact factor: 7.580
Authors: Jinrui Dong; Wei-Wen Lim; Shamini G Shekeran; Jessie Tan; Sze Yun Lim; Joyce Wei Ting Goh; Benjamin L George; Sebastian Schafer; Stuart A Cook; Anissa A Widjaja Journal: Int J Mol Sci Date: 2022-06-25 Impact factor: 6.208